ClinicalTrials.gg
TerminatedNCT01399593Updated Oct 3, 2017Results posted

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

A Phase 2 interventional study of Eculizumab in Antibody Mediated Rejection, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 41 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-03.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Why this study was terminated
Did not achieve statistical significance for primary endpoint

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization therapy.

Read the detailed description

The main objective of this study was to evaluate the safety and efficacy of eculizumab to prevent AMR in sensitized recipients of living donor kidney transplants requiring desensitization therapy prior to transplantation. The primary endpoint focused on acute AMR during the first 9 weeks post-transplantation.

Patients were to be vaccinated against N. meningitidis at least 14 days prior to study drug initiation and revaccinated 30 days later. If not vaccinated 14 days prior, prophylactic antibiotics were to be administered. Pre-transplant infectious disease assessment was to be performed as part of the screening assessment.

Patients were to undergo desensitization therapy according to the practice of the local transplant center prior to transplantation, and this desensitization practice was to be uniformly applied for all patients at that center throughout the study. The actual length of desensitization for an individual patient was based on the clinical judgment of the Transplant Center team. Rituximab was prohibited in all patients as part of the pre-transplantation desensitization therapy due to potential pharmacodynamic interactions.

The control group was designed to test eculizumab against the best available care (referred to as standard of care, or SOC) consisting of plasmapheresis (PP) and/or intravenous immunoglobulin (IVIg). The best available care consisting of PP and IVIg was chosen because these modalities combined represented the most prevalent therapy reported in the literature and were the best available therapies at the time of this protocol's inception as per the transplant community.

02

Conditions studied

  • Antibody Mediated Rejection

Keywords

  • Antibody Mediated Rejection
  • AMR
  • Acute Humoral Rejection
  • AHR
  • Living Donor
  • Kidney Transplant
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥18 years old
  2. Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation

Exclusion criteria

Exclusion Criteria:

  1. ABO incompatible with living donor
  2. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.

    Drug: Eculizumab

  • No intervention
    Standard of Care

    Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Failure Rate

    The primary efficacy variable was a binary outcome variable where patients meeting the composite endpoint of the occurrence of 1) biopsy-proven acute AMR, 2) graft loss, 3) patient death, or 4) loss to follow-up definition at Week 9 post-transplantation were considered treatment failures and all others were considered treatment successes.

    Time frame: 9 weeks post-transplantation

07

Results

Posted Apr 19, 2017
Limitations and caveats
Data interpretation confounded by open-label study with potential reporting bias, unequal exposure to randomized prevention therapy between groups, some patients in SOC arm received eculizumab for treatment of AMR, all patients immunosuppressed.

Participant flow

Recruitment period lasted from Nov 2011 to Mar 2014. Forty-one sites in Australia, the European Union, and North America participated in this study.

Participant flow — Overall Study
MilestoneEculizumabStandard of Care
Started5151
Completed4849
Not completed32
Withdrew: Physician decision10
Withdrew: Adverse event10
Withdrew: Death11
Withdrew: Transplantectomy01

Outcome measures

PrimaryTreatment Failure Rate

The primary efficacy variable was a binary outcome variable where patients meeting the composite endpoint of the occurrence of 1) biopsy-proven acute AMR, 2) graft loss, 3) patient death, or 4) loss to follow-up definition at Week 9 post-transplantation were considered treatment failures and all others were considered treatment successes.

Time frame:
9 weeks post-transplantation
Reported as:
Count of participants · Participants
Treatment Failure Rate
ParticipantsEculizumabStandard of Care
Treatment Failure Rate57
Statistical analysis
  • Eculizumab vs Standard of Care · Fisher Exact · p = 0.76 · Proportion difference: -3.9 · 95% CI -23.9 to 16.3

Adverse events

Collected over Adverse events were collected throughout the 3-year study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab1/51 (2%)43/51 (84.3%)51/51 (100%)
Standard of Care1/51 (2%)48/51 (94.1%)51/51 (100%)
Most frequent serious events
Showing 10 of 165
Most frequent serious events
EventEculizumabStandard of Care
Kidney transplant rejectionImmune system disorders22/5128/51
DiarrhoeaGastrointestinal disorders3/518/51
Urinary tract infectionInfections and infestations2/517/51
Escherichia urinary tract infectionInfections and infestations4/516/51
LymphoceleVascular disorders3/515/51
GastroenteritisInfections and infestations0/514/51
PneumoniaInfections and infestations3/514/51
PyelonephritisInfections and infestations4/512/51
UrosepsisInfections and infestations4/512/51
BronchitisInfections and infestations2/513/51
Most frequent other events
Showing 10 of 113
Most frequent other events
EventEculizumabStandard of Care
AnaemiaBlood and lymphatic system disorders16/5128/51
Urinary tract infectionInfections and infestations28/5118/51
DiarrhoeaGastrointestinal disorders22/5127/51
NauseaGastrointestinal disorders26/5119/51
LeukopeniaBlood and lymphatic system disorders16/5123/51
Oedema peripheralGeneral disorders15/5121/51
Kidney transplant rejectionImmune system disorders19/5117/51
PyrexiaGeneral disorders12/5116/51
HyperglycaemiaMetabolism and nutrition disorders14/5116/51
HypophosphataemiaMetabolism and nutrition disorders16/5112/51

Baseline characteristics

Age, Customized
Age, Customized(Participants)EculizumabStandard of Care (SOC)Total
In utero000
Preterm newborn - gestational age < 37 wk000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)474996
From 65 to 84 years426
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)EculizumabStandard of Care (SOC)Total
Female373067
Male142135
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EculizumabStandard of Care (SOC)Total
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American6612
White373673
More than one race000
Unknown or Not Reported6612
Region of Enrollment
Region of Enrollment(Participants)EculizumabStandard of Care (SOC)Total
Australia415
France3710
Germany112
Italy246
Netherlands033
Norway112
Spain347
Sweden145
United Kingdom10515
United States262147
Total Donor-Specific Antibodies (DSA)
Total Donor-Specific Antibodies (DSA)(mean fluorescence intensity (MFI))EculizumabStandard of Care (SOC)Total
Mean15394.7 ± 14163.7817469.8 ± 12573.4416411.1 ± 13380.16
Highest Single Donor-Specific Antibodies (DSA)
Highest Single Donor-Specific Antibodies (DSA)(mean fluorescence intensity (MFI))EculizumabStandard of Care (SOC)Total
Mean8135 ± 4048.088740.7 ± 4289.978431.7 ± 4157.87
08

Study locations

41 sites
  • Birmingham, Alabama 35294, United States
  • La Jolla, California 92037, United States
  • Los Angeles, California 90095, United States
  • San Francisco, California 94143, United States
  • Washington, D.C., District of Columbia 20007, United States
  • Atlanta, Georgia 30309, United States
  • Chicago, Illinois 60612, United States
  • Baltimore, Maryland 21205, United States
  • Boston, Massachusetts 02115, United States
  • Rochester, Minnesota 55905, United States
  • Saint Louis, Missouri 63110, United States
  • Livingston, New Jersey 07039, United States
  • New York, New York 10032, United States
  • Chapel Hill, North Carolina 27599, United States
  • Cincinnati, Ohio 45267, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Houston, Texas 77030, United States
  • North Terrace, South Australia 5000, Australia
  • Camperdown, 2050, Australia
  • Clayton VIC, 3168, Australia
  • Parkville VIC, 3050, Australia
  • Paris, 75010, France
  • Paris, 75743, France
  • Toulouse Cedex, 31059, France
  • Tours Cedex, 37044, France
  • Dresden, 01307, Germany
  • Heidelberg, 69120, Germany
  • Milan, 20162, Italy
  • Padova, 35128, Italy
  • Rotterdam, 3015 CE, Netherlands
  • Oslo, N-0027, Norway
  • Barcelona, 8036, Spain
  • Göteborg, 413 45, Sweden
  • Huddinge, SE 141 86, Sweden
  • Uppsala, S 751 85, Sweden
  • London, England SE1 9RT, United Kingdom
  • London, England W12 0HS, United Kingdom
  • Oxford, England OX3 7LJ, United Kingdom
  • Birmingham, B15 2TH, United Kingdom
  • Cambridge, CB2 2QQ, United Kingdom
  • Coventry, CV2 2DX, United Kingdom
09

References and documents

Publications

  • Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, Rowshani AT, Colvin RB, Dain B, Boice JA, Glotz D; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. Am J Transplant. 2019 Oct;19(10):2876-2888. doi: 10.1111/ajt.15364. Epub 2019 Apr 19. PubMed 30887675 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2011 to primary completion in May 2014, 30 months.

Results were first posted in Apr 2017, 2 years 11 months after primary completion. A results delay was requested in Nov 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2011
First posted
Jul 22, 2011
StartActual
Nov 2, 2011
Primary completionActual
May 13, 2014
CompletionActual
Nov 13, 2015
Results delay requested
Nov 18, 2016
Results first posted
Apr 19, 2017
Last update
Oct 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01399593
Responsible party
Sponsor
First posted
Jul 22, 2011
Start date
Nov 2, 2011
Primary completion
May 13, 2014
Completion
Nov 13, 2015
Results posted
Apr 19, 2017
Last update
Oct 3, 2017

Study contacts

Masayo Ogawa, MD
study director · Alexion Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion